Clinical trials
catalyst calendar across sponsors →Studies where DNTH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 14 tracked-famous managers (CITADEL ADVISORS LLC, Artisan Partners Limited Partnership, Qube Research & Technologies Ltd, Balyasny Asset Management L.P., MARSHALL WACE, LLP, +9 more) · FINRA short interest 9.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)NCT06858579Part B: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Claseprubart, Claseprubart, Placebo | Chronic Inflammatory Demyelinating Polyneuropathy | 256 | 2028-12-31 | in 865 d | 2026-08-18 |
| A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)NCT07647510Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Claseprubart, Placebo · Combination product: Claseprubart, Placebo | Myasthenia Gravis, Generalized | 195 | Dec 2028 | ≤ 865 d | 2026-07-08 |
| A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyNCT06537999Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Claseprubart, Placebo | Multifocal Motor Neuropathy | 46 | Dec 2026 | ≤ 134 d | 2026-08-10 |
| A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)NCT06282159Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Claseprubart, Placebo | Myasthenia Gravis, Generalized | 65 | 2025-07-28actual | — | 2026-07-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19